Pilot study of submucosal radiofrequency for epistaxis in hereditary hemorrhagic telangiectasia

Rhinology

Volumn 51, Issue 4, 2013, Pages 355-360

  Mortuaire, G ^a   Boute, O ^a   Hatron, P Y ^a   Chevalier, D ^a  

^a UNIV LILLE   (France)

Author keywords

Epistaxis; Hereditary hemorrhagic telangiectasia; Radiofrequency; Treatment technique

Indexed keywords

ADULT; ARTICLE; CLINICAL TRIAL; ENDOSCOPY; EPISTAXIS; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; NOSE MUCOSA; NOSE SEPTUM; PILOT STUDY; PROSPECTIVE STUDY; RADIOSURGERY; RENDU OSLER WEBER DISEASE; TREATMENT OUTCOME;

ADULT; ENDOSCOPY; EPISTAXIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NASAL MUCOSA; NASAL SEPTUM; PILOT PROJECTS; PROSPECTIVE STUDIES; RADIOSURGERY; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TREATMENT OUTCOME;

EID: 84890048235     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: 10.4193/Rhino13.027     Document Type: Article

References (20)

1. Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000; 91: 66-67.
2. Olitsky SE. Topical timolol for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. Am J Otolaryngol. 2012; 33: 375-376.
3. Samson G, García de la Calera A, Dupuis-Girod S, et al. Ex vivo study of bevacizumab transport through porcine nasal mucosa. Eur J Pharm Biopharm. 2012; 80: 465-469.
4. Yaniv E, Preis M, Shevro J, Nageris B, Hadar T. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia-a long-term clinical trial. Rhinology. 2011; 49: 214-216.
5. Chen S, Karnezis T, Davidson TM. Safety of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope. 2011; 121: 644-646.
6. Brinkerhoff BT, Choong NW, Treisman JS, Poetker DM. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia. Am J Otolaryngol. 2012; 33: 349-351.
7. Lund VJ, Howard DJ. Closure of the nasal cavities in the treatment of refractory hereditary haemorrhagic telangiectasia. J Laryngol Otol. 1997; 111: 30-33.
8. Lund VJ, Howard DJ. A treatment algorithm for the management of epistaxis in hereditary hemorrhagic telangiectasia. Am J Rhinol. 1999; 13: 319-322.
9. Lin HC, Lin PW, Friedman M, et al. Long-term results of radiofrequency turbinoplasty for allergic rhinitis refractory to medical therapy. Arch Otolaryngol Head Neck Surg. 2010; 136: 892-895.
10. Loaëc M, Morinière S, Hitier M, Ferrant O, Plauchu H, Babin E. Psychosocial quality of life in hereditary haemorrhagic telangiectasia patients. Rhinology. 2011; 49: 164-167.
11. Al-Deen S, Bachmann-Harildstad G. A grading scale for epistaxis in hereditary haemor-rhagic teleangectasia. Rhinology. 2008; 46: 281-284.
12. Ichimura K, Kikuchi H, Imayoshi S, Yamauchi T, Ishikawa K. Are patients with severe epistaxis caused by hereditary hemorrhagic telangiectasia satisfied with nostril closure surgery? Auris Nasus Larynx. 2012; 39: 59-64.
13. Morais D, Millás T, Zarrabeitia R, Botella LM, Almaraz A. Local sclerotherapy with polydocanol (Aethoxysklerol®) for the treatment of Epistaxis in Rendu-Osler-Weber or Hereditary Hemorrhagic Telangiectasia (HHT): 15 years of experience. Rhinology. 2012; 50: 80-86.
14. Borsik M, Herbreteau D, Deffrennes D, et al. [Treatment of epistaxis in Rendu-Osler disease by intramucosal injection of ethibloc]. Ann Otolaryngol Chir Cervicofac. 1992; 109: 273-276.
15. Ichimura K, Kikuchi H, Imayoshi S. A new method of nasal dermoplasty (MW grafting method) in patients with large septal perforation. Laryngoscope. 2011; 121: 1715-1717.
16. Farmer SE, Eccles R. Understanding sub-mucosal electrosurgery for the treatment of nasal turbinate enlargement. J Laryngol Otol. 2007; 121: 615-622.
17. Kakarala K, Faquin WC, Cunningham MJ. Radiofrequency volumetric tissue reduction of the inferior turbinate in a sheep model. Laryngoscope. 2012; 122: 724-729.
18. Gouveris H, Nousia C, Giatromanolaki A, et al. Inferior nasal turbinate wound healing after submucosal radiofrequency tissue ablation and monopolar electrocautery: histologic study in a sheep model. Laryngoscope. 2010; 120: 1453-1459.
19. Simonds J, Miller F, Mandel J, Davidson TM. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope. 2009; 119: 988-992.
20. Dheyauldeen S, Ostertun Geirdal A, Osnes T, Vartdal LS, Dollner R. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose. Laryngoscope. 2012; 122: 1210-1214.